Objective:
To discuss findings from the phase 2 ARCHER trial of vonaprument and their implications for the ongoing phase 3 ARCHER II study.
Approach:
- Trial Overview: The ARCHER trial evaluated vonaprument, a nonpegylated Fab targeting C1q, in patients with geographic atrophy (GA).
- Risk Factor Analysis: The trial identified baseline risk factors for 15-letter vision loss, focusing on patients with compromised vision and subfoveal lesions.
Key Findings:
- Patients with vision between 20/40 and 20/100 were at highest risk for 15-letter loss.
- Subfoveal lesions increased the risk of 15-letter loss compared to nonsubfoveal lesions.
Interpretation:
The findings from the ARCHER trial informed the design of the phase 3 ARCHER II study, aiming to improve outcomes for patients with GA.
Conclusion:
The phase 3 ARCHER II study is expected to read out later this year.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.